X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership is focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $1,035.0 million Upfront Cash: $35.0 million
Deal Type: Partnership April 22, 2024
Details:
Proceeds will support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases.
Lead Product(s): siRNA Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Khosla Ventures
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 10, 2022
Details:
Funding will be used to develop RNA therapies for transplant and chronic liver diseases. Ochre Bio has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines.
Lead Product(s): RNA Therapies
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Khosla Ventures
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Financing June 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
